- KCSA Strategic Communications has signed an agreement to provide investor relations services to Mindset Pharma (MSET)
- KCSA is a fully integrated communications consultancy firm that will provide strategic support for Mindset’s research of next-generation psychedelic compounds
- Mindset Pharma is a drug discovery and development company focused on creating psychedelic medicines
- Mindset Pharma Inc. (MSET) is up 1.85 per cent and is currently trading at $0.55 per share
KCSA Strategic Communications has signed an agreement to provide investor relations services to Mindset Pharma (MSET).
The agreement, effective May 15, has an initial term of six months.
KCSA is a fully integrated communications consultancy with a creative and strategic approach to public relations, investor relations and social media.
Mindset Pharma is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.
KCSA will provide strategic support for this research by reaching out to potential investors and marketing the compound.
Jeffrey Goldberger, managing partner and principal of KCSA Strategic Communications commented,
“KCSA is excited to partner with the management team of Mindset to help increase investor awareness of this very exciting CNS-focused drug development company.”
Jeffrey added,
“As a firm dedicated to supporting the medical psychedelics industry, KCSA is well versed in the sector and is confident the underlying science of psychedelic compounds holds great promise in treating a variety of psychiatric disorders.”
The agreement may be terminated with 90 days’ written notice by either party following the conclusion of the initial six-month term.
Mindset Pharma is a drug discovery and development company focused on creating psychedelic medicines to treat neurological and psychiatric disorders.
Mindset Pharma Inc. (MSET) is up 1.85 per cent and is trading at $0.55 per share as of 3:59 pm ET.